Clinical Trial Update: A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 study of ABI-2280 Vaginal Insert for Cervical Intraepithelial Neoplasia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Intraepithelial Neoplasia

Drugs mentioned

• ABI-2280 Vaginal Insert (ABI-2280 vaginal insert)

Snippet

Sponsor: Antiva Biosciences | Conditions: Cervical Intraepithelial Neoplasia | Phase 1, Phase 2 | Status: TERMINATED